Biocompatibility of thermo-responsive hydrogel ocular drug delivery system

热响应水凝胶眼部给药系统的生物相容性

基本信息

批准号：
7940224
负责人：
JENNIFER J Kang-Mieler
金额：
$ 36.09万
依托单位：
ILLINOIS INSTITUTE OF TECHNOLOGY
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-09-30 至 2013-09-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7940224
关键词：
Age related macular degeneration Area Biocompatible Materials Blindness Blood Vessels Body Temperature Bolus Infusion Characteristics Choroidal Neovascularization Clinical Clinical Data Diabetic Retinopathy Diagnosis Disease Drug Delivery Systems Electroretinography Encapsulated Gel Goals Hemorrhage Histology Hydrogels Image Implant In Vitro Inflammation Injection of therapeutic agent Laboratories Lasers Liquid substance Methods Needles Ophthalmoscopes Optical Coherence Tomography Patients Posterior eyeball segment structure Property Proteins Regimen Research Retina Retinal Rodent Model Scanning Site Solid Solutions System Testing Time Toxic effect Treatment Protocols Vascular Diseases Vascular Endothelial Growth Factors Venous angiogenesis biomaterial compatibility blood flow measurement drug efficacy implantation improved in vivo innovation novel response

项目摘要

DESCRIPTION (provided by applicant): Recently employed anti-vascular endothelial growth factor (VEGF) therapy is a very promising treatment for the wet form of age-related macular degeneration and diabetic retinopathy. To be effective, multiple intravitreal injections are needed every four to six weeks. This is not a desirable method as it is associated with several inherent complications. Currently, there is no alternative method; hence, there is a great need to develop a relatively non-invasive delivery method that is more effective than the current clinical regimen. The proposed drug delivery system uses thermo-responsive hydrogel that would optimize the anti-angiogenic effects but minimize the potential for ectopic effects of a large bolus delivery. Due to its novel thermo-responsive characteristic, the hydrogel can be injected as a liquid form to the juxtascleral region or vitreous cavity via a small gauge needle. Once exposed to the body temperature, the solution will become a solid gel that will release the anti-VEGF agents. In vitro studies have demonstrated that thermo-responsive hydrogels can encapsulate and release active protein. The goal of this proposal is to investigate the feasibility and biocompatibility of thermo-responsive hydrogel as an ocular drug delivery system in vivo. Specific Aim 1 will investigate the biocompatibility of the thermo-responsive implant in either the vitreous cavity or juxtascleral region in an in vivo rodent model. To evaluate biocompatibility, electroretinogram (ERG) responses, scanning laser ophthalmoscope (SLO)-imaging blood flow measurements, spectral domain optical coherence tomography (SD-OCT) imaging and histological examination of retinal toxicity and inflammation will be performed at various time points after the implantation. Specific Aim 2 will determine the efficacy of released anti-VEGF from the hydrogels to suppress angiogenic responses in a laser-induced choroidal neovascularization rodent model. ERG responses, SLO-imaging blood flow measurements, OCT imaging and histology will be used to evaluate the efficacy. Widespread clinical use of anti-VEGF necessitates a practical and effective delivery method to the posterior segment. The innovation of this project is that a novel biomaterial will be used to minimize the need for repeated intravitreal injections and improve the efficacy of the drug. The proposed drug delivery system will have a great impact on the current treatment regimen. PUBLIC HEALTH RELEVANCE: Widespread clinical use of anti-vascular endothelial growth factor (VEGF) therapy necessitates a practical and effective delivery method to the posterior segment of the eye. Recently developed biodegradable thermo- responsive hydrogel system has demonstrated to encapsulate and release active protein. The overall goal of this proposal is to investigate the feasibility and biocompatibility of thermo-responsive hydrogel as an ocular drug delivery system which can have a significant impact on the current treatment of age-related macular degeneration and diabetic retinopathy.

描述（由申请人提供）：最近采用的抗血管内皮生长因子（VEGF）疗法是治疗湿性年龄相关性黄斑变性和糖尿病视网膜病变的非常有前途的疗法。为了有效，需要每四到六周进行多次玻璃体内注射。这不是一种理想的方法，因为它与一些固有的并发症相关。目前，没有替代方法；因此，非常需要开发一种比目前临床方案更有效的相对无创的递送方法。所提出的药物输送系统使用热响应水凝胶，可以优化抗血管生成作用，同时最大限度地减少大剂量输送产生异位效应的可能性。由于其新颖的热响应特性，水凝胶可以通过小规格针以液体形式注射到巩膜旁区域或玻璃体腔。一旦暴露于体温，溶液将变成固体凝胶，释放抗 VEGF 药物。体外研究表明，热响应水凝胶可以封装和释放活性蛋白。该提案的目的是研究热响应水凝胶作为体内眼部药物输送系统的可行性和生物相容性。具体目标 1 将研究体内啮齿动物模型中玻璃体腔或巩膜旁区域的热响应植入物的生物相容性。为了评估生物相容性，将在术后不同时间点进行视网膜电图（ERG）反应、扫描激光检眼镜（SLO）成像血流测量、谱域光学相干断层扫描（SD-OCT）成像以及视网膜毒性和炎症的组织学检查。植入。具体目标 2 将确定水凝胶中释放的抗 VEGF 药物在激光诱导的脉络膜新生血管啮齿动物模型中抑制血管生成反应的功效。 ERG 反应、SLO 成像血流测量、OCT 成像和组织学将用于评估疗效。抗 VEGF 的广泛临床应用需要一种实用且有效的后段递送方法。该项目的创新之处在于，将使用一种新型生物材料来最大限度地减少重复玻璃体内注射的需要，并提高药物的疗效。所提出的药物输送系统将对当前的治疗方案产生很大的影响。公众健康相关性：抗血管内皮生长因子 (VEGF) 疗法的广泛临床应用需要一种实用且有效的眼后段递送方法。最近开发的可生物降解的热响应水凝胶系统已被证明可以封装和释放活性蛋白质。该提案的总体目标是研究热响应水凝胶作为眼部药物输送系统的可行性和生物相容性，这对当前年龄相关性黄斑变性和糖尿病视网膜病变的治疗产生重大影响。